Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Mast cells are involved in many disorders where the triggering mechanism that leads to degranulation and/or cytokine secretion has not been defined. Several chronic inflammatory diseases are associated with increased mast cell numbers and upregulation of the TNF receptor family member CD30, but the role of elevated CD30 expression is poorly understood. Here we report what we believe to be a novel way to activate mast cells with CD30 that leads to degranulation-independent secretion of chemokines. CD30 induced a de novo synthesis and secretion of the chemokines IL-8, macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-1beta, a process involving the MAPK/ERK pathway. Mast cells were found to be the predominant CD30 ligand-positive (CD30L-positive) cell in the chronic inflammatory skin diseases psoriasis and atopic dermatitis, and both CD30 and CD30L expression were upregulated in lesional skin in these conditions. Furthermore, the number of IL-8-positive mast cells was elevated both in psoriatic and atopic dermatitis lesional skin as well as in ex vivo CD30-treated healthy skin organ cultures. In summary, characterization of CD30 activation of mast cells has uncovered an IgE-independent pathway that is of importance in understanding the entirety of the role of mast cells in diseases associated with mast cells and CD30 expression. These diseases include Hodgkin lymphoma, atopic dermatitis, and psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“Over time, a more versatile role has been identified for these potent effector cells, highlighting the broad spectrum of functions that mast cells have in health and disease (1).”
Background
Cited by
MicroRNAs: Novel Regulators Involved in the Pathogenesis of Psoriasis?
Sonkoly, E., Wei, T., Janson, P. C. J., Sääf, A., Lundeberg, L., Tengvall-Linder, M., Norstedt, G., Alenius, H., Homey, B., Scheynius, A., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000610 · Cited by 754
“In psoriasis, there is evidence for the pathogenic relevance of several different cell types that normally occur in skin: keratinocytes [12], fibroblasts [13], monocyte-derived immunocytes [11,14], T cells [15], and mast cells [16].”
BackgroundTheoharides, T. C., Alysandratos, K.-D., Angelidou, A., Delivanis, D.-A., Sismanopoulos, N., Zhang, B., Asadi, S., Vasiadi, M., Weng, Z., Miniati, A., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.014 · Cited by 680
IgE, Mast Cells, and Eosinophils in Atopic Dermatitis
Liu, F.-T., Goodarzi, H., & Chen, H.-Y. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8252-4 · Cited by 470
Differential release of mast cell mediators and the pathogenesis of inflammation
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00519.x · Cited by 425
Mast cells in the promotion and limitation of chronic inflammation
Metz, M., Grimbaldeston, M. A., Nakae, S., Piliponsky, A. M., Tsai, M., & Galli, S. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00520.x · Cited by 302
Metadata
- Authors
- Fischer, M., Harvima, I. T., Carvalho, R. F. S., Möller, C., Naukkarinen, A., Enblad, G., & Nilsson, G.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-10-02
- Volume
- 116
- Issue
- 10
- Pages
- 2748-2756
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1977313091
- Cited by
- 141
- References
- 1
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.